No products in the cart.
Diagnostic Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies (anti-Protein induced by vitamin K absence-II, anti-PIVKA-Ⅱ) and antigens (recombinant Protein induced by vitamin K absence-II (PIVKA-Ⅱ) protein) for Cancer PIVKA-Ⅱ detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Cat:GMP-h-PIVKA-Ⅱ
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Cancer (hepatocellular carcinoma) and related syndrome. GeneMedi offers paired diagnostics grade Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies (monoclonal antibody, mab) and antigens for Cancer (hepatocellular carcinoma) rapid test kit of Protein induced by vitamin K absence-II (PIVKA-Ⅱ) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Cancer (hepatocellular carcinoma ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC).
Protein induced by vitamin K absence-II (PIVKA-II), also known as des-γ-carboxy-prothrombin, has been identified as a serum biomarker linked to HCC. It is an abnormal prothrombin molecule produced as a consequence of an acquired defect in the posttranslational carboxylation of the prothrombin precursor in malignant cells. A quite large body of evidence indicates that PIVKA-II levels in the blood are increased in patients with HCC and importantly, an increasing amount of data indicates that it is more sensitive than AFP for differentiating HCC at all stages from patients with cirrhosis or chronic hepatitis. In addition, several studies from Asian countries have shown that serum PIVKA-II levels correlate with the HCC stage, as well as with survival of HCC patients, and a combination of PIVKA-II and AFP is currently used in Japan for HCC diagnosis and surveillance in accordance with the recommendations of the Clinical Practice Guidelines for HCC of that country.
Product Description
Cat No. of Pruducts
GMP-h-PIVKA-Ⅱ-Ag01:Recombinant Human PIVKA-Ⅱ Protein
Product Name
Recombinant Human PIVKA-Ⅱ Protein
Target
Protein induced by vitamin K absence-II
Alias of Target/Biomarker
#N/A
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in PIVKA-Ⅱ level test of Cancer (hepatocellular carcinoma) and related syndrome evaluation
Tag
His
Products description
Recombinant Human PIVKA-Ⅱ Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous
Next
Cat No. of Pruducts
GMP-h-PIVKA-Ⅱ-Ab01,GMP-h-PIVKA-Ⅱ-Ab02
Product Name
Anti-Human PIVKA-Ⅱ mouse monoclonal antibody (mAb)
Target
Protein induced by vitamin K absence-II (PIVKA-Ⅱ)
Alias of Target/Biomarker
#N/A
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies in PIVKA-Ⅱ level test of Cancer (hepatocellular carcinoma) and related syndrome evaluation.
Tag
mFc
Products description
Anti-Human PIVKA-Ⅱ mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
